1,452 results on '"Untch, M."'
Search Results
52. Axilläres Downstaging mit neoadjuvanter Chemotherapie: Eine retrospektive multizenter Analyse von 720 Patientinnen.
53. Adjuvante Therapierealität bei Patienten mit einem primären Mammakarzinom: Eine retrospektive Registerstudie zur Bewertung der endokrinen Therapie-Strategien und Ergebnisse für prämenopausale primäre Brustkrebs-Patientinnen mit einem mittlerem und hohem Rezidivrisiko (CLEAR B)
54. PREcoopERA Window-of-Opportunity trial of giredestrant+/- triptorelin vs. anastrozole+triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.
55. Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer- LOBSTER.
56. Ist eine mögliche Serom-Entstehung nach Mastektomie bei Brustkrebs durch Vorerkrankungen antizipierbar? – Ergebnisse der SerMa pilot Studie.
57. CAPTOR-BC – Umfassende Analyse der räumlichen, zeitlichen und molekularen Muster zur Vorhersage der Wirksamkeit und Resistenz von Ribociclib bei Patientinnen mit fortgeschrittenem Brustkrebs.
58. Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer – a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial.
59. Fluoreszenzverteilung in Genitaldysplasien nach ALA-Applikation
60. Durchflußzytometrische Untersuchungen zur Wirkung von delta-Aminolävulinsäure (ALA) und Photodynamische Lasertherapie (PDT) auf den Zellzyklus von Zervixkarzinomzellinien
61. Einsatz der photodynamsichen Lasertherapie bei Genitaldysplasien
62. Vergleich von CYFRA 21-1, TPA und TPS beim Bronchialkarzinom, Blasenkarzinom und bei benignen Erkrankungen
63. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis
64. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery
65. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
66. Systemtherapie beim Mammakarzinom
67. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element
68. Prognoserelevanz disseminierter Tumorzellen im Knochenmark: Prospective Studie an 1045 Mammakarzinom — Patientinnen im Stadium I – III
69. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC
70. Reply to letter to the editor ‘Primum non nocere’ by Templeton and Šeruga
71. Neue Möglichkeiten der medikamentösen Antiemesistherapie
72. 132P Health economic properties of palbociclib in breast cancer patients with high risk of relapse following neoadjuvant therapy: Results from the Penelope-B trial
73. 199TiP Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA
74. 119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial
75. 122MO Quality of life from the Penelope-B study on high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib
76. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
77. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis
78. Ex-utero-intrapartum-treatment-Manöver
79. Neoadjuvante Therapie beim Mammakarzinom: Indikationen und Evaluation des Ansprechens
80. 13. Internationale St.-Gallen-Konferenz 13. bis 16. März 2013: Behandlung des primären Mammakarzinoms
81. Trastuzumab-Deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer (BC) after neoadjuvant therapy (NAT): a randomized, phase 3 trial (DESTINY-Breast05)
82. 66P Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto
83. 17P Impact of body mass index (BMI) on prognostic and predictive value of stromal tumour-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): A pooled analysis of six neoadjuvant trials
84. 21P BACH1 and HIF1α predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC)
85. Neoadjuvante Systemtherapie beim Mammakarzinom
86. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
87. Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer—a problem still to be solved
88. Behandlung der Patientinnen mit HER2- (ErbB2-) positivem Mammakarzinom: Ein Paradebeispiel für die Übertragung molekularer Erkenntnisse in die Klinik
89. Trastuzumab emtansine for residual invasive HER2-positive breast cancer
90. Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)†
91. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
92. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
93. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
94. Long-term outcomes of patients with node-negative, <= 3cm, HER2+breast cancer (BC) enrolled in ALTTO
95. Immunologische Therapie beim Mammakarzinom
96. Schwangerschaftsassoziiertes Mammakarzinom: Diagnostik und Therapie
97. The high-grade endometrial sarcoma: a rare entity
98. Bedeutung des Non-Sentinel-Lymphknoten beim Mammakarzinom
99. Indikationen zur Sentinellymphknotenentfernung beim Mammakarzinom
100. Chemotherapie: Langzeitnebenwirkungen aus gynäkologisch-onkologischer Sicht
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.